Closed-loop and Open-loop Devices for Blood Glucose Control in Normal and Diabetic Subjects

(All are verbatim summaries) Albisser, A. M., Leibel, B. S., Ewart, T. G., Davidovac, Z., Botz, C. K., and Zingg, W. (Dept. of Med. Eng. and Surg. Res., Hosp. for Sick Children, Banting and Best Dept. DIABETES, VOL. 28, NO. 1 81 CLOSED-LOOP AND OPEN-LOOP DEVICES FOR BLOOD GLUCOSE CONTROL of Med. Res., and Inst. of Med. Sci., Univ. of Toronto, and Dept. of Rehab. Med., Wellesley Hosp., Toronto, Canada): An Artificial Endocrine Pancreas. Diabetes23:389,1974. In order to regulate the blood sugar in the intact depancreatized dog as precisely as that accomplished by its normal pancreas, specific equipment has been devised to deliver insulin or glucose continuously and establish normoglycemia both in the fasting and glucose-loaded states. A minicomputer was programmed to respond to the constantly monitored whole blood glucose by injecting appropriate insulin or glucose intravenously to maintain or restore the normal blood sugar. Standardized glucose challenges consisting of uniform infusions of 10 mg. glucose per kg. min. for sixty minutes were applied to assess the performance of the artificial pancreas. Direct control which relates insulin dosage to the level of the circulating blood sugar results in a response to the challenge resembling mild maturity-onset diabetes both in the abnormally high blood sugar response to glucose loading and in the large amount of insulin required to effect a return to normoglycemia. In contrast, control based on projected (predicted) values of blood sugar not only prevents the abnormal rise but consumes in some cases only 10 per cent of the insulin used for the same glucose load. The performance of the system parallels that of the normal pancreas and lends support to the hypothesis that biphasic insulin responses to glucose challenges are essential for the economy of insulin and the precision of regulation seen in healthy subjects. Pfeiffer, E. F., Thum, Ch., and Clemens, A. H. (Dept. of Endocrinol. and Metab., Centr. of Intern. Med. and Pediatr., Univ. of Ulm, Germany, and Life Science Instruments, Miles Lab , Elkhart, Ind.): The Artificial Beta Cell—A Continuous Control of Blood Sugar by External Regulation of Insulin Infusion (Glucose Controlled Insulin Infusion System). Horm. Metab. Res. 6:339,1974." Continuous control of blood sugar in diabetics without dietary restriction has been effected by a Glucose Controlled Insulin Infusion System (GCIIS) consisting of an automatic blood glucose determination apparatus, a dedicated microcomputer, allowing the optimal adaptation of the diabetic to the artificial endocrine pancreas, a special insulin pump and an automatic printer. Insulin-dependent juvenile diabetics and diabetic subjects suffering from diabetic coma and ketoacidosis were successfully controlled and corrected for various periods of time, exhibiting completely normal blood glucose values despite unrestricted food intake. Future developments are seen on the one hand in the further improvement of the present apparatus for complete automatic treatment of acute diabetic conditions, e.g. diabetic coma, preand post-operative care of the diabetic subject, including correction of electrolyte and other disturbances. On the other hand, a smaller portable instrument should permit the diabetic subject temporarily after food intake to maintain completely normal blood glucose concentrations, preventing the presently unavoidable excessive blood glucose fluctuations. Kraegen, E. W., Campbell, L. V., Chia, Y. 0., Meier, H., and Lazarus, L. (Garvan Inst. of Med. Res., St. Vincent's Hosp., Sydney, Australia): Control of Blood Glucose in Diabetics Using an Artificial Pancreas. Aust. N. Z. J. Med. 7:280, 1977. Studies have been performed using an on-line computer system programmed for blood glucose control of insulin and dextrose infusion (artificial pancreas). The aim of these studies was to test performance of the artificial pancreas and to suggest directions for future optimisation. Blood glucose stabilisation studies of diabetic volunteers were extended throughout the day and included three main meals and light exercise periods. Monitoring of blood glucose profiles of the same diabetics after depot insulin were performed on a separate occasion for comparison. The presence of insulin antibodies did not impair operation of the artificial pancreas. Most of the insulin infused by the artificial pancreas was to initially correct hyperglycaemia with relatively little required to subsequently maintain euglycaemia. The afternoon intra-meal average infusion rate was 0.9 U/hr. It is suggested that correction of fasting hyperglycaemia and maintenance of euglycaemia in diabetics be treated as separate control problems for the artificial pancreas. The overall ability of the artificial pancreas to control blood glucose to a degree not attainable by conventional insulin therapy is confirmed, in this case under conditions which include patient activity. Slama, G., Hautecouverture, M., Assan, R., and Tchobroutsky, G. (Dept. of Diabetes, Univ. of Paris VI, Hotel-Dieu Hosp., Paris, France): One to Five Days of Continuous Intravenous Insulin Infusion on Seven Diabetic Patients. Diabetes 23:732, 1974." Regular insulin was infused from one to five days in seven adult diabetic volunteers previously treated with subcutaneous insulin three times a day. Through a catheter inserted in a peripheral vein, a small pump delivered 66 ± 10 units of insulin per day in a 131.0 ± 4.0 ml. solution at mean rates of 26 ± 4 mU./min. between meals and 373 ± 58 rnU/ min. during meals; 40 per cent of the total daily dose was given during the three meal periods. These rates were precalculated. Patients were ambulatory. Blood glucose was assayed every fifteen minutes for eight hours during the postprandial periods and hourly otherwise. The overall highest mean values were observed ninety minutes after breakfast (138 ± 17 mg./100 ml.) and four hours after dinner (121 ± 18); the lowest were 73 ± 7, 64 ± 7, 72 ± 15 at the end of the three high concentration insulin infusion periods and 56 ± 7 at 6 a.m. During insulin infusions the mean values of blood glucose parameters were as follows: 89 ± 7 mg./100 ml. for the mean blood glucose level; 66 ± 9 for the mean amplitude of glycemic excursion; and 17 ± 5 for the modified Schlichtkrull's M coefficient. Insulin infusions gave significantly lower blood glucose levels during the night and at breakfast than insulin three times a day and higher blood glucose values before lunch. Both technics gave very good control of diabetes. Insulin infusions without blood glucose monitoring are feasible for several days in ambulatory patients. Genuth, S., and Martin, P. (Saltzman Inst. for Clin. Invest, and Div. of Invest. Med., Mount Sinai Hosp. of Cleveland, and Case Western Reserve Univ. Sch. of Med., Cleveland, 82 DIABETES, VOL. 28, NO. 1 JULIO V. SANTIAGO AND ASSOCIATES Ohio): Control of Hyperglycemia in Adult Diabetics by Pulsed Insulin Delivery. Diabetes 26:571, 1977." Nine adult diabetic subjects were treated for two weeks by an intravenous insulin-delivery system that provided preprogramed five-hour pulses of insulin with each meal such that a normal diurnal pattern of plasma insulin was attained. Plasma insulin peaked at 800 per cent of basal and at approximately 45 minutes after the onset of each pulse. On day 14, mean plasma glucose (hourly sampling x 22) was 94 mg./100 ml., with a range of 66 to 125 mg./100 ml. Eighty-eight per cent of all values were between 50 and 150 mg./100 ml. The dose of insulin required correlated significantly with the degree of obesity. On the first posttreatment day, hourly plasma glucose remained significantly below pretreatment levels while the endogenous plasma insulin area increased 46 per cent above pretreatment values (p < 0.01). Six of the patients still exhibited slight improvement in glucose tolerance for seven days while on diet but not on insulin treatment. It is concluded that insulin replacement, coordinated with meals in a physiologic manner, can virtually normalize plasma glucose even without feedback control of delivery rates. Definite but transient remission of beta-cell dysfunction may follow. Deckert, T., and Lorup, B. (Steno Mem. Hosp., Gentofte, Denmark): Regulation of Brittle Diabetics By A Preplanned Insulin Infusion Programme. Diabetologia 12: 573, 1976. Eleven brittle diabetics, mean duration 11.5 years, all treated with highly purified porcine NPH insulin twice daily, were placed on highly purified porcine regular insulin 4 times daily for 2 days. Thereafter pre-planned intravenous insulin infusion was started. Insulin in an amount corresponding to the daily insulin requirement was infused by a mobile electric infusion pump at precalculated rates between 30 and 7 ml/hour during 2 days. The patients were ambulatory. Capillary blood glucose was taken every 30 min. after meals and every two hours during the night. After an equilibration period of 7 hours, blood glucose fluctuations were in the physiological range in nearly all patients during the infusion period. [Only 1.3% of the blood samples showed glucose levels lower than 2.5 mmol/l and 2.9% levels exceeding 10.0 mmol/l during the infusion days]. Mean blood glucose (MBG) was 6.0 ± 0.9 mmol/l (mean ± s.d.), the standard deviation of MBG was 1.8 ± 0.5 mmol/l, the mean amplitude of blood glucose excursions (MAGE) 4.7 ± 1.4 mmol/l, and glucosuria 3.1 ± 3.9 g/day. All these data of glucose homeostasis were significantly lower during the infusion days. The incidence of hypoglycaemic attacks was low (0.32/patient/day) and not significantly higher than during NPH treatment. It is concluded that near normal blood glucose fluctuations can be achieved in brittle diabetics by pre-planned insulin infusion without blood glucose monitoring. Marliss, E. B., Murray, F. T., Stokes, E. F., Zinman, B., Nakhooda, A. F., Denoga, A., Leibel, B. S., and Albisser, A. M. (Dept. of Med., Toronto Gen. Hosp., and Res. In

[1]  M. T. Brennan,et al.  Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. , 1967, The Journal of clinical investigation.

[2]  E. Pfeiffer,et al.  Antidiabetic Action of Somatostatin–Assessed by the Artificial Pancreas , 1975, Diabetes.

[3]  G. Slama,et al.  One to Five Days of Continuous Intravenous Insulin Infusion on Seven Diabetic Patients , 1974, Diabetes.

[4]  G. Tomkin,et al.  HOME MONITORING OF BLOOD-GLUCOSE , 1978, The Lancet.

[5]  S. Genuth,et al.  Control of Hyperglycemia in Adult Diabetics by Pulsed Insulin Delivery , 1977, Diabetes.

[6]  A. H. Kadish,et al.  AUTOMATION CONTROL OF BLOOD SUGAR. I. A SERVOMECHANISM FOR GLUCOSE MONITORING AND CONTROL. , 1964, The American journal of medical electronics.

[7]  P. Blackshear,et al.  One year of continuous heparinization in the dog using a totally implantable infusion pump. , 1975, Surgery, gynecology & obstetrics.

[8]  A H Clemens,et al.  The development of Biostator, a Glucose Controlled Insulin Infusion System (GCIIS). , 1977, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[9]  K. Alberti,et al.  Small doses of intramuscular insulin in the treatment of diabetic "coma". , 1973, Lancet.

[10]  W. Clarke,et al.  The Effect of Hyperglucagonemia on Blood Glucose Concentrations and on Insulin Requirements in Insulin-requiring Diabetes Mellitus , 1978, Diabetes.

[11]  S P Bessman,et al.  Prototype for an implantable micropump powdered by piezoelectric disk benders. , 1975, Transactions - American Society for Artificial Internal Organs.

[12]  E. Kraegen,et al.  Control of blood glucose in diabetics using an artificial pancreas. , 1977, Australian and New Zealand journal of medicine.

[13]  P. Felig,et al.  Influence of Oral Glucose Ingestion on Splanchnic Glucose and Gluconeogenic Substrate Metabolism in Man , 1975, Diabetes.

[14]  W Zingg,et al.  Studies with an artificial endocrine pancreas. , 1977, Archives of internal medicine.

[15]  Charles K. Botz An Improved Control Algorithm for an Artificial ß-Cell , 1976, IEEE Transactions on Biomedical Engineering.

[16]  R E Gander,et al.  Comparison of Peripheral and Portal Routes of Insulin Infusion by a Computer-controlled Insulin Infusion System (Artificial Endocrine Pancreas) , 1976, Diabetes.

[17]  K. Moxness,et al.  Continuous blood glucose analysis in ambulatory fed subjects. I. General methodology. , 1968, Mayo Clinic proceedings.

[18]  H Keen,et al.  Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. , 1978, British medical journal.

[19]  L. C. Clark,et al.  ELECTRODE SYSTEMS FOR CONTINUOUS MONITORING IN CARDIOVASCULAR SURGERY , 1962 .

[20]  D. Porte A receptor mechanism for the inhibition of insulin release by epinephrine in man. , 1967, The Journal of clinical investigation.

[21]  J. Gerich,et al.  Lack of Glucagon Response to Hypoglycemia in Diabetes: Evidence for an Intrinsic Pancreatic Alpha Cell Defect , 1973, Science.

[22]  P. Cryer,et al.  The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. , 1976, The Journal of clinical investigation.

[23]  T. Danowski,et al.  Jet Injection of Insulin During Self-Monitoring of Blood Glucose , 1978, Diabetes Care.

[24]  H. Mehnert,et al.  Glucose homeostasis under continuous intravenous insulin therapy in diabetics. , 1977, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[25]  Wilfred Peter Charette Control systems theory applied to metabolic homeostatic systems and the derivation and identification of mathematical models. , 1969 .

[26]  A H Clemens,et al.  Development and evaluation of a glucose analyzer for a glucose controlled insulin infusion system ((Biostator). , 1978, Clinical chemistry.

[27]  G. Brown,et al.  An improved technique for continuous in vivo analysis of glucose. , 1966, Clinica chimica acta; international journal of clinical chemistry.

[28]  E. Cerasi,et al.  A Mathematical Model for the Glucose Induced Insulin Release in Man , 1974, European journal of clinical investigation.

[29]  J. Hiebert,et al.  Progress Towards an Implantable Glucose Sensor and an Artificial Beta Cell , 1973 .

[30]  W. Clarke,et al.  Glucagon, insulin and glucose response to physiologic testing in normal and massively obese adults. , 1977, Metabolism: clinical and experimental.

[31]  G. Kessler,et al.  CONTINUOUS IN VIVO DETERMINATION OF BLOOD GLUCOSE IN HUMAN SUBJECTS , 1960, Annals of the New York Academy of Sciences.

[32]  R. Sridhar,et al.  A mathematical model for the control mechanism of free fatty acid-glucose metabolism in normal humans. , 1970, Computers and biomedical research, an international journal.

[33]  A. Matas,et al.  Current Status of Islet and Pancreas Transplantation in Diabetes , 1976, Diabetes.

[34]  W. Clarke,et al.  The characteristics of a new glucose sensor for use in an artificial pancreatic beta cell. , 2008, Artificial organs.

[35]  H. E. Martin,et al.  Response of Diabetic Coma to Various Insulin Dosages , 1954, Diabetes.

[36]  A H Clemens,et al.  The artificial beta cell--a continuous control of blood sugar by external regulation of insulin infusion (glucose controlled insulin infusion system). , 1974, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[37]  W. Malaisse,et al.  Effects of adrenergic and cholinergic agents upon insulin secretion in vitro. , 1967, Endocrinology.

[38]  R. Varco,et al.  Chronic heparin anticoagulant in dogs by continuous infusion with a totally implantable pump. , 1975, Transactions - American Society for Artificial Internal Organs.

[39]  R. D. Schultz,et al.  Continuous Extracorporeal Monitoring of Animal Blood Using the Glucose Electrode , 1976, Diabetes.

[40]  W Kerner,et al.  Attempts at perfect normalization of glucose tolerance test of severe diabetics by artificial beta cell. , 1976, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[41]  Kuo Wei Chang,et al.  VALIDATION AND BIOENGINEERING ASPECTS OF AN IMPLANTABLE GLUCOSE SENSOR , 1973, Transactions - American Society for Artificial Internal Organs.

[42]  W. Zingg,et al.  A Computer Analog of the Endocrine Pancreas , 1973 .

[43]  S. Genuth Plasma insulin and glucose profiles in normal, obese, and diabetic persons. , 1973, Annals of internal medicine.

[44]  R. D. Schultz,et al.  PROTOTYPE GLUCOSE‐OXYGEN SENSOR FOR THE ARTIFICIAL PANCREAS , 1973, Transactions - American Society for Artificial Internal Organs.

[45]  W Zingg,et al.  Clinical Control of Diabetes by the Artificial Pancreas , 1974, Diabetes.

[46]  S. Raptis,et al.  Differences in insulin, growth hormone and pancreatic enzyme secretion after intravenous and intraduodenal administration of mixed amino acids in man. , 1973, The New England journal of medicine.

[47]  B. Zinman,et al.  Insulinoma Resection Facilitated by the Artificial Endocrine Pancreas , 1978, Diabetes.

[48]  J. Brown,et al.  Identification and actions of gastric inhibitory polypeptide. , 1975, Recent progress in hormone research.

[49]  G. Sachs,et al.  BIOELECTRODES FOR TISSUE METABOLISM * , 1968, Annals of the New York Academy of Sciences.

[50]  G. Hicks,et al.  The Enzyme Electrode , 1967, Nature.

[51]  B. Zinman,et al.  Normalization of Glycemia in Diabetics During Meals with Insulin and Glucagon Delivery by the Artificial Pancreas , 1977, Diabetes.

[52]  D. A. Hall,et al.  A new method for the continuous monitoring of blood glucose by measurement of dissolved oxygen. , 1965, Clinical chemistry.